3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Glioblastoma
4
Glioma
3
Multiple Myeloma
2
Lymphoma
2
Astrocytoma
2
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Carcinoma
1
Advanced Fallopian Tube Carcinoma
1
Interventions
Cyclophosphamide
328
Methotrexate
182
Cytarabine
164
fludarabine phosphate
151
Vincristine
128
Dexamethasone
126
fludarabine
123
Peripheral Blood Stem Cell Transplantation
116
Whole-Body Irradiation
108
Etoposide
106
Mycophenolic Acid
105
Tacrolimus
95
Busulfan
95
Filgrastim
93
Melphalan
81
Cyclosporine
80
Rituximab
79
Doxorubicin
79
Mercaptopurine
70
Radiotherapy
62
Antilymphocyte Serum
62
Prednisone
57
Granulocyte Colony-Stimulating Factor
57
blinatumomab
55
pegaspargase
54
Asparaginase
54
Thiotepa
52
Daunorubicin
52
Calcium Dobesilate
47
Clofarabine
45
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Tetanus Toxoid
×
Clear all
NCT01611298
2020-04-21
TAR
Baylor College of Medicine
Phase NA
Completed
7 enrolled
8 charts